

# WEEKLY EPIDEMIOLOGICAL REPORT

## A publication of the Epidemiology Unit Ministry of Health

231, de Saram Place, Colombo 01000, Sri Lanka Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk Web: http://www.epid.gov.lk

Vol. 51 No. 52

21st - 27th Dec 2024

Rift Valley Fever: A zoonotic threat linking animal and human health globally - II

This is the second article of two in a series on "Rift Valley Fever: A zoonotic threat linking animal and human health globally"

tally to safeguard veterinary and laboratory personnel at high risk of RVF exposure. Research is ongoing to develop additional vaccine candidates.

#### Impact on animals

RVF causes high mortality rates in newborn livestock, particularly sheep and goats, and leads to significant economic losses. Pregnant animals are particularly vulnerable, and RVF can cause abortion waves during outbreaks. The virus is transmitted through mosquito-host interactions, and infected livestock can serve as a source of virus transmission, especially during movement or trade.

#### **Diagnosis**

Accurate diagnosis of RVF is essential for effective treatment and control, as its symptoms often overlap with those of other diseases. Early clinical diagnosis is challenging due to the nonspecific nature of RVF symptoms, which can resemble other viral hemorrhagic fevers, malaria, or typhoid fever. Definitive diagnosis of RV involves laboratory methods such as RT-PCR, ELISA, and virus isolation.

## Treatment

Most human cases of RVF are mild and selflimiting, requiring no specific treatment. For severe cases, supportive therapy is the primary approach to managing the disease.

An inactivated vaccine for human use has been developed, but it is not yet licensed or commercially available. It has been utilized experimen-

## **Prevention and Control**

During outbreaks of RVF, close contact with infected animals and their bodily fluids is the primary risk factor for human transmission. The risk of infection can be minimized through safe practices in animal husbandry, avoiding unsafe slaughtering methods, maintaining proper hygiene, and refraining from consuming fresh blood, raw milk, or animal tissues in affected areas.

Key strategies for prevention and control include:

- Animal vaccination: Conduct preventive vaccination campaigns for livestock during non-outbreak periods to reduce the spread of the virus among animals.
- Public health education: Train at-risk groups on safe handling of animal products, proper use of personal protective equipment, and measures to prevent mosquito bites.
- **Vector control**: Manage mosquito populations by eliminating breeding sites.
- Surveillance: Implement continuous monitoring systems to track animal health and environmental conditions, including rainfall patterns, to predict and mitigate potential outbreaks.

Contents	Page
1. Rift Valley Fever: A zoonotic threat linking animal and human health globall	y - II 1
2. Summary of selected notifiable diseases reported ( $14^{th} - 20^{th}$ Dec 2024)	3
3. Surveillance of vaccine preventable diseases & AFP (14th – 20th Dec 2024)	4

#### Public health education and risk reduction

Raising awareness about RVF risk factors and protective measures is essential to minimize infections. Key public health actions include:

- Reducing animal-to-human transmission: Encourage the use of gloves, personal protective equipment, and safe animal husbandry. Promote proper hand hygiene.
- Safe consumption practices: Advice against consuming fresh blood, raw milk, or raw animal tissues.
  Ensure animal products are thoroughly cooked in endemic regions.
- Preventing mosquito bites: Promote mosquito protection with insecticide-treated nets, repellents, light-coloured clothing, and limiting outdoor activities during peak mosquito times.
- Targeted vector control: Identify and treat mosquito breeding sites, though efforts may need adaptation during extensive flooding.

### Infection control in healthcare settings

Although human-to-human transmission of RVF has not been documented, there remains a theoretical risk of transmission to healthcare workers through exposure to infected blood or tissues. To mitigate this risk, healthcare and laboratory personnel managing suspected or confirmed RVF cases should adhere to standard precautions when handling patient specimens.

#### RVF forecasting and climatic models

Forecasting models help predict climatic conditions linked to RVF outbreaks, especially during periods of above-average rainfall, such as during the El Niño–Southern Oscillation. Early warning systems using satellite and climate data can detect animal cases early, enabling timely preventive actions to reduce epidemic risks.

## Global collaboration and the one health approach

International organizations such as the World Health Organization (WHO), the Food and Agriculture Organization (FAO), and the World Organization for Animal Health (WOAH) promote the One Health approach as a comprehensive strategy to address Rift Valley Fever (RVF). This approach emphasizes the integration of human, animal, and environmental health sectors to effectively manage and prevent RVF outbreaks.

## Compiled by:

Dr Aruni Hathamuna Senior Registrar Epidemiology Unit

#### **References:**

- CDC. (2024, May 14). About Rift Valley Fever (RVF). Rift Valley Fever.
  - https://www.cdc.gov/rift-valley-fever/about/index.html
- Facts about Rift Valley fever. (n.d.). European Centre for Disease Prevention and Control. https://www.ecdc.europa.eu/en/rift-valley-fever/facts
- 3. Rift Valley fever. (n.d.). WOAH World Organization for Animal Health. https://www.woah.org/en/disease/rift-valley-fever/
- 4. World Health Organization. (2018, February 19). *Rift Valley fever*. Who.int; World Health Organization: WHO.

https://www.who.int/news-room/fact-sheets/detail/rift-valley-fever

Table 1: Selected notifiable diseases reported by Medical Officers of Health 14th-20th Dec 2024 (51st Week)

rab		. •	eiec	lou		IIIau	ie c	IISE	45E	ן איני	oorte	<i>-</i>	у и	lear	oui '	Ollic	cers	OI I	пеа		14"	-20		ec z	UZ4	(5)	lar A	vee	N)
O.	*5	100	100	100	100	100	100	100	100	100	93	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	66	
WRCD	<u>*</u>	100	80	87	100	100	100	92	100	94	98	100	100	22	100	100	100	92	100	85	87	89	94	80	06	73	100	93	
losis	В	2165	1176	929	629	127	272	461	162	170	260	34	99	20	32	158	108	137	465	236	286	411	245	133	395	361	140	8975	
Tuberculosis	⋖	42	25	59	38	0	က	8	4	0	10	0	0	4	0	က	0	7	ω	0	2	~	က	4	19	∞	~	227	
nania-	В	7	33	2	99	384	2	2	497	125	~	က	4	13	18	4	28	19	672	38	897	609	47	263	182	34	0	3848	
Leishmania-	A	0	0	0	0	7	0	0	5	က	0	0	0	~	0	0	0	0	16	~	12	10	2	7	7	3	0	69	
Meningitis	В	09	153	89	16	24	19	111	36	79	34	7	17	28	∞	52	42	23	283	88	74	35	42	103	149	96	36	1686	
Meni	⋖	2	9	~	_	0	0	က	2	0	_	0	က	2	_	0	0	0	4	2	0	0	~	2	4	_	0	36	
xodue	В	603	537	869	424	155	300	897	317	387	241	17	12	48	13	186	144	118	099	144	320	168	417	194	381	959	244	8584	
Chickenpox	4	6	18	15	=	က	0	4	က	~	12	~	0	~	0	ω	2	4	20	~	∞	7	10	4	က	16	7	185	
H. Rabiies	В	0	0	_	က	0	0	2	2	0	_	2	0	0	က	2	_	0	4	_	_	~	0	_	4	_	0	30	
H. Ra	⋖	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Viral Hep.	В	6	4	12	15	7	7	13	12	28	7	0	_	4	0	56	7	4	7	2	18	69	28	74	34	16	4	463	
Vir	∢	0	10	0 0	0	0 9	_	1	1	7	0	0	0 +	0 9	0	3 2	2 0	0	0 9	0	~	3	2	1	1	1	5 0	16	
Typhus F.	В	0 10	1 15	0 10	3 43	0	0 54	2 130	1 49	0 30	7 626	1	0 14	0	0 11	0	0	0 15	1 45	2 44	0 33	0	1 56	0 37	4 39	2 35	0	5 1337	
	⋖										3 37																	3 55	
Leptospirosis	В	623	1034	1012	302	144	179	1051	563	694	188	37	41	127	96	102	237	167	1122	319	492	325	497	732	2180	974	06	13328	
Lepi	4	7	28	35	10	13	5	27	28	13	119	7	4	10	17	9	က	7	55	15	25	00	13	18	44	42	5	268	
F. Poisoning	В	25	88	41	75	32	228	114	20	38	49	2	7	24	28	29	24	15	373	4	54	33	58	98	51	16	31	1625	
F. P.	⋖	0	5	_	0	0	2	~	0	0	_	0	0	2	0	~	0	0	0	0	~	0	0	_	16	0	_	32	
En. Fever	В	0 49	1 16	0 38	0 10	0 8	0 12	0 12	0 7	0 4	1 32	1 3	0	0 2	0 0	2 0	0 0	0 3	0 3	0 4	0	0	6 0	0 3	1 10	0 11	0 2	4 250	
	∢		42	3	)	4	ω	22 (	4	)	2	0	0	_	_	19	4	_	40	4	ω	8		2	4	18	_		
Encephalitis	В	0 11	4	0	0	0	0	0 2	0	0	0	0	0	0	_	0 1	0	0	0	0	0	0	0 11	0	0 1	_	0	3 240	
	В А	49	52	37	44	21	157	64	30	15	62	19	9	13	12	136	42	25	29	20	38	29	46	22	137	36	22	1222	
Dysentery	A	က	2	0	~	_	0	0	_	0	2	~	0	0	0	2	0	~	0	0	0	0	က	0	2	က	<b>—</b>	23 12	
Fever	В	11348	5729	2708	4505	1042	343	2121	863	1159	5625	319	331	192	224	1627	266	752	2198	1250	787	412	885	1016	2868	1959	716	51245	
<b>Dengue Fever</b>	A	220	103	49	22	52	က	27	22	12	9/	9	∞	4	7	35	_	19	25	39	22	က	20	13	20	17	2	860	
RDHS		Colombo	Gampaha	Kalutara	Kandy	Matale	Nuwara Eliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmunai	SRILANKA	

Source: Weekly Returns of Communicable Diseases (esurvillance.epid.gov.Ik). T=Timeliness refers to returns received on or before 20 th Dec, 2024 Total number of reporting units 358 Number of reporting units data provided for the current week. B = Cumulative cases for the year.

Table 2: Vaccine-Preventable Diseases & AFP

14th - 20th Dec 2024 (51st Week)

Disease	No. of Cases by Province										Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date	
	W	С	S	N	Е	NW	NC	U	Sab	week in 2024	week in 2023	2024	2023	in 2024 & 2023	
AFP*	00	00	01	00	01	01	00	01	00	04	01	76	95	-20%	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Mumps	01	00	00	01	00	02	01	01	01	07	02	282	226	24.7 %	
Measles	00	00	00	00	00	00	00	00	00	00	08	297	788	-62.3 %	
Rubella	00	00	00	00	00	00	00	00	00	00	00	02	09	-77.7%	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	02	-100 %	
Tetanus	00	00	00	00	00	00	00	00	00	00	00	05	06	-16.6 %	
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Japanese Enceph- alitis	00	00	00	00	00	00	00	00	00	00	00	14	06	133.3 %	
Whooping Cough	00	00	00	00	01	00	00	00	00	01	00	72	07	928.5 %	

#### Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam,

AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP\* (Acute Flaccid Paralysis ), Japanese Encephalitis

CRS\*\* =Congenital Rubella Syndrome

NA = Not Available

Take prophylaxis medications for leptospirosis during the paddy cultivation and harvesting seasons.

It is provided free by the MOH office / Public Health Inspectors.

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

## ON STATE SERVICE

Dr. H. A. Tissera Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10